Scarica l'app Stockscreener
17.56
1.27%
0.2661
Precedente Chiudi:
$17.29
Aprire:
$17.38
Volume 24 ore:
68,565
Relative Volume:
0.37
Capitalizzazione di mercato:
$1.18B
Reddito:
$-9,000
Utile/perdita netta:
$-68.03M
Rapporto P/E:
-16.72
EPS:
-1.05
Flusso di cassa netto:
$-44.76M
1 W Prestazione:
-9.04%
1M Prestazione:
+5.23%
6M Prestazione:
+3.67%
1 anno Prestazione:
+0.69%
Intervallo 1D:
$17.38
$18.10
Intervallo di 1 settimana:
$16.76
$19.35
Portata 52W:
$13.77
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Nome
Pulse Biosciences Inc
Settore
Industria
Telefono
510-906-4600
Indirizzo
3957 POINT EDEN WAY, HAYWARD, CA
Confronta PLSE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
17.56 | 1.16B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
435.46 | 156.44B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
183.32 | 53.99B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
270.08 | 39.41B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
75.14 | 36.63B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
265.69 | 18.78B | 2.96B | 487.70M | 344.00M | 6.6758 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | Oppenheimer | Outperform |
| 2021-07-27 | Iniziato | Stephens | Overweight |
| 2021-03-11 | Iniziato | Maxim Group | Buy |
| 2021-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-12 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Pulse Biosciences Inc Borsa (PLSE) Ultime notizie
Is this a good reentry point in Pulse Biosciences Inc.Portfolio Update Summary & Weekly High Return Stock Opportunities - newser.com
Why hedge funds are buying Pulse Biosciences Inc. stockJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
Tick level data insight on Pulse Biosciences Inc. volatilityWeekly Gains Summary & Long-Term Capital Growth Ideas - newser.com
Using data filters to optimize entry into Pulse Biosciences Inc.July 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com
Using fundamentals and technicals on Pulse Biosciences Inc.Portfolio Performance Report & High Return Trade Opportunity Guides - newser.com
Sector ETF performance correlation with Pulse Biosciences Inc.2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Visualizing Pulse Biosciences Inc. stock with heatmapsBear Alert & Detailed Earnings Play Strategies - newser.com
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse - Yahoo Finance
Will Pulse Biosciences Inc. stock beat EPS estimates2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Pulse Biosciences (PLSE): Assessing Valuation After Recent Share Price Swings - Yahoo Finance
Pulse Biosciences’ Npulse successful in epicardial PFA - BioWorld MedTech
Pulse Biosciences Reveals Positive First-in-Human PFA Data - Medical Product Outsourcing
Is Pulse Biosciences Inc. stock bottoming outJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
Pulse Biosciences announces presentation of late-breaking data from the nPulse cardiac surgical system - MarketScreener
Pulse Biosciences Announces Results from nPulse Cardiac Surgical System Study - TradingView
Pulse Biosciences reports positive results for cardiac ablation system By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - MarketScreener
Pulse Biosciences reports positive results for cardiac ablation system - Investing.com India
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Is now a turning point for Pulse Biosciences Inc.July 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Pulse Biosciences (NASDAQ:PLSE) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Heatmap analysis for Pulse Biosciences Inc. and competitorsJuly 2025 Trends & Long-Term Capital Growth Strategies - newser.com
Will Pulse Biosciences Inc. continue its uptrendMarket Activity Summary & Real-Time Sentiment Analysis - newser.com
What analysts say about Pulse Biosciences Inc 6L8 stockTrendline Breakouts & Outstanding Investment Portfolio - earlytimes.in
Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells 4,600 Shares of Stock - MarketBeat
Pulse Biosciences introduces nPulse Vybrance for nsPFA technology - Traders Union
Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Investing News Network
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Pulse Biosciences (PLSE) Is Up 11.1% After FDA Clears Cardiac Ablation StudyWhat's Changed - Sahm
Pulse Biosciences (PLSE): Evaluating Its Valuation After Recent Investor Interest - Sahm
Using Ichimoku Cloud for Pulse Biosciences Inc. technicals2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
What does recent volatility data suggest for Pulse Biosciences Inc.Buy Signal & Momentum Based Trading Signals - newser.com
Pulse Biosciences Expands Equity Incentive Plan - MSN
Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial - Insider Monkey
Pulse Biosciences Inc Azioni (PLSE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pulse Biosciences Inc Azioni (PLSE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
5.62%
0.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):